

# CITATION REPORT

List of articles citing

## Association of Hydroxychloroquine With QTc Interval in Patients With COVID-19

DOI: 10.1161/circulationaha.120.048476  
Circulation, 2020, 142, 513-515.

**Source:** <https://exaly.com/paper-pdf/76816791/citation-report.pdf>

**Version:** 2024-04-20

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
30	Repurposing existing drugs for COVID-19: an endocrinology perspective. <i>BMC Endocrine Disorders</i> , <b>2020</b> , 20, 149	3.3	28
29	The C-C Chemokine Receptor Type 4 Is an Immunomodulatory Target of Hydroxychloroquine. <i>Frontiers in Pharmacology</i> , <b>2020</b> , 11, 1253	5.6	1
28	Biological, molecular and pharmacological characteristics of chloroquine, hydroxychloroquine, convalescent plasma, and remdesivir for COVID-19 pandemic: A comparative analysis. <i>Journal of King Saud University - Science</i> , <b>2020</b> , 32, 3159-3166	3.6	9
27	Update I. A systematic review on the efficacy and safety of chloroquine/hydroxychloroquine for COVID-19. <i>Journal of Critical Care</i> , <b>2020</b> , 59, 176-190	4	44
26	Frequency of Long QT in Patients with SARS-CoV-2 Infection Treated with Hydroxychloroquine: A Meta-analysis. <i>International Journal of Antimicrobial Agents</i> , <b>2020</b> , 56, 106212	14.3	9
25	The effect of favipiravir on QTc interval in patients hospitalized with coronavirus disease 2019. <i>Journal of Electrocardiology</i> , <b>2020</b> , 63, 115-119	1.4	8
24	COVID-19: The experience from Iran. <i>Clinics in Dermatology</i> , <b>2021</b> , 39, 23-32	3	5
23	Toxicity of chloroquine and hydroxychloroquine following therapeutic use or overdose. <i>Clinical Toxicology</i> , <b>2021</b> , 59, 12-23	2.9	24
22	Cardiovascular adverse events associated with hydroxychloroquine and chloroquine: A comprehensive pharmacovigilance analysis of pre-COVID-19 reports. <i>British Journal of Clinical Pharmacology</i> , <b>2021</b> , 87, 1432-1442	3.8	26
21	Targeting Endolysosomal Two-Pore Channels to Treat Cardiovascular Disorders in the Novel COronaVirus Disease 2019. <i>Frontiers in Physiology</i> , <b>2021</b> , 12, 629119	4.6	9
20	Cardiovascular Health and Disease in the Context of COVID-19. <i>Cardiology Research</i> , <b>2021</b> , 12, 67-79	1.8	7
19	COVID-19 and Cardiac Arrhythmias. <i>European Journal of Arrhythmia &amp; Electrophysiology</i> , <b>2021</b> , 7, 33	0.3	0
18	Endolysosomal Ca signaling in cardiovascular health and disease. <i>International Review of Cell and Molecular Biology</i> , <b>2021</b> , 363, 203-269	6	8
17	Viral myocarditis: 1917-2020: From the Influenza A to the COVID-19 pandemics. <i>Trends in Cardiovascular Medicine</i> , <b>2021</b> , 31, 163-169	6.9	10
16	QTc prolongation in COVID-19 patients treated with hydroxychloroquine, chloroquine, azithromycin, or lopinavir/ritonavir: A systematic review and meta-analysis. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2021</b> , 30, 694-706	2.6	13
15	Modelling sudden cardiac death risks factors in patients with coronavirus disease of 2019: the hydroxychloroquine and azithromycin case. <i>Europace</i> , <b>2021</b> , 23, 1124-1133	3.9	2
14	QTc interval prolongation, inflammation, and mortality in patients with COVID-19. <i>Journal of Interventional Cardiac Electrophysiology</i> , <b>2021</b> , 1	2.4	0

13	Peculiar Aspects of Patients with Inherited Arrhythmias during the COVID-19 Pandemic. <i>Arquivos Brasileiros De Cardiologia</i> , <b>2021</b> , 117, 394-403	1.2	0
12	Electrocardiographic manifestations of COVID-19: Effect on cardiac activation and repolarization. <i>EClinicalMedicine</i> , <b>2021</b> , 39, 101057	11.3	0
11	Early COVID-19 Therapy with Azithromycin Plus Nitazoxanide, Ivermectin or Hydroxychloroquine in Outpatient Settings Significantly Reduced Symptoms Compared to Known Outcomes in Untreated Patients.		4
10	Arrhythmogenic Risk and Mechanisms of QT-Prolonging Drugs to Treat COVID-19.. <i>Cardiac Electrophysiology Clinics</i> , <b>2022</b> , 14, 95-104	1.4	0
9	In vitro ion channel profile and ex vivo cardiac electrophysiology properties of the R(-) and S(+) enantiomers of hydroxychloroquine. <i>European Journal of Pharmacology</i> , <b>2021</b> , 174670	5.3	1
8	Arrhythmias in COVID-19.. <i>Methodist DeBakey Cardiovascular Journal</i> , <b>2021</b> , 17, 73-82	2.1	3
7	Antimicrobial agents and torsades de pointes. <b>2022</b> , 231-266		
6	DataSheet_1.pdf. <b>2020</b> ,		
5	DataSheet_2.pdf. <b>2020</b> ,		
4	Image_1.pdf. <b>2020</b> ,		
3	Safety of Short-Term Treatments with Oral Chloroquine and Hydroxychloroquine in Patients with and without COVID-19: A Systematic Review. <i>Pharmaceuticals</i> , <b>2022</b> , 15, 634	5.2	1
2	The cross-talk of lung and heart complications in COVID-19: Endothelial cells dysfunction, thrombosis, and treatment. 9,		0
1	Possible relationship between hydroxychloroquine and electrocardiographic and echocardiographic abnormalities in patients with inflammatory rheumatic diseases: a monocentric study. 096120332211498		0